Cardiovascular Genetic Testing Market Report 2026

Cardiovascular Genetic Testing Market Overview

• Cardiovascular Genetic Testing market size has reached to $3.93 billion in 2025 • Expected to grow to $6.62 billion in 2030 at a compound annual growth rate (CAGR) of 11% • Growth Driver: Rising Prevalence Of Cardiovascular Diseases Fueling The Growth Of The Market Due To Increasing Demand For Early Risk Detection And Personalized Treatment • Market Trend: Innovative Clinician-Ordered Genetic Tests Enhancing Personalized Cardiovascular Risk Assessment • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Cardiovascular Genetic Testing Market?

Cardiovascular genetic testing refers to the analysis of an individual’s DNA to identify inherited genetic variations that increase the risk of developing heart and blood vessel disorders, enabling early diagnosis, personalized treatment planning, and targeted preventive strategies. It helps clinicians predict disease susceptibility, guide medication selection, assess familial risk, and support proactive management of cardiovascular conditions through precision medicine approaches. The main testing types of cardiovascular genetic testing include predictive testing, carrier testing, prenatal and newborn testing, diagnostic testing, pharmacogenomic testing, and other testing types. Predictive testing refers to genetic tests that assess an individual’s risk of developing cardiovascular conditions before symptoms appear. These tests are used for diseases such as inherited cardiomyopathies, hypertrophic cardiomyopathy, dilated cardiomyopathy, arrhythmia, aortopathies, and other diseases. The technologies involved include cytogenetic testing, biochemical testing, and molecular testing. The applications include chromosome analysis, genetic disease diagnosis, cardiovascular disease diagnosis, and other applications, and the end users are hospitals and clinics, diagnostic laboratories, research institutions, genetic counseling centers, pharmaceutical companies, and direct-to-consumer testing.

What Is The Cardiovascular Genetic Testing Market Growth Forecast?

The cardiovascular genetic testing market size is expected to see rapid growth in the next few years. It will grow to $6.62 billion in 2030 at a compound annual growth rate (CAGR) of 11.0%. The growth in the forecast period can be attributed to increasing demand for precision medicine approaches, rising adoption of population-based genetic screening, expansion of AI-driven variant interpretation, growing integration of genomics in clinical decision making, increasing focus on preventive cardiovascular healthcare. Major trends in the forecast period include increasing adoption of predictive genetic risk assessment, rising use of multigene panel testing, growing integration of bioinformatics and AI analytics, expansion of pharmacogenomic testing applications, enhanced focus on personalized cardiovascular care.

Global Cardiovascular Genetic Testing Market Segmentation

1) By Testing Type: Predictive Testing; Carrier Testing; Prenatal And Newborn Testing; Diagnostic Testing; Pharmacogenomic Testing; Other Testing Types 2) By Disease: Inherited Cardiomyopathies; Hypertrophic Cardiomyopathy (HCM); Dilated Cardiomyopathy (DCM); Arrhythmia; Aortopathies; Other Diseases 3) By Technology: Cytogenetic Testing; Biochemical Testing; Molecular Testing 4) By Application: Chromosome Analysis; Genetic Disease Diagnosis; Cardiovascular Disease Diagnosis; Other Applications 5) By End User: Hospitals And Clinics; Diagnostic Laboratories; Research Institutions; Genetic Counseling Centers; Pharmaceutical Companies; Direct-To-Consumer Testing Subsegments: 1) By Predictive Testing: Presymptomatic Risk Assessment; Familial Variant Screening; Polygenic Risk Evaluation; Late Onset Disease Prediction; Susceptibility Gene Testing 2) By Carrier Testing: Autosomal Recessive Carrier Screening; Linked Carrier Screening; Expanded Carrier Screening Panels; Single Gene Carrier Screening; Family History Based Carrier Testing 3) By Prenatal And Newborn Testing: Non Invasive Prenatal Genetic Testing; Invasive Prenatal Diagnostic Testing; Newborn Metabolic Screening; Congenital Heart Disease Genetic Screening; Neonatal Gene Panel Testing 4) By Diagnostic Testing: Single Gene Diagnostic Testing; Multigene Panel Diagnostic Testing; Whole Exome Diagnostic Testing; Whole Genome Diagnostic Testing; Variant Confirmation Testing 5) By Pharmacogenomic Testing: Drug Response Gene Testing; Adverse Drug Reaction Risk Testing; Dose Optimization Genetic Testing; Anticoagulant Response Testing; Cardiovascular Drug Metabolism Testing 6) By Other Testing Types: Cascade Family Testing; Population Based Genetic Screening; Research Use Genetic Testing; Confirmatory Follow Up Testing; Clinical Trial Genetic Testing

What Is The Driver Of The Cardiovascular Genetic Testing Market?

The increasing prevalence of cardiovascular diseases is expected to propel the growth of the cardiovascular genetic testing market going forward. Cardiovascular diseases (CVDs) are a group of disorders affecting the heart and blood vessels, including conditions such as heart attacks, strokes, and hypertension. The prevalence of cardiovascular diseases is rising primarily due to increasing sedentary lifestyles associated with urbanization, which contribute to obesity, hypertension, and metabolic disorders. The increasing incidence of cardiovascular diseases drives demand for cardiovascular genetic testing, as detecting genetic risks early enables personalized prevention and treatment strategies to lower the likelihood of serious heart complications. For instance, in January 2024, according to the American Heart Association, a US-based non-profit organization, the age-adjusted death rate from cardiovascular disease increased to 233.3 per 100,000 in 2024, up 4.0% from 224.4 per 100,000 in 2023. Therefore, the increasing prevalence of cardiovascular disease is driving the growth of the cardiovascular genetic testing industry.

Key Players In The Global Cardiovascular Genetic Testing Market

Major companies operating in the cardiovascular genetic testing market are Labcorp Holdings Inc., Quest Diagnostics Inc., ICON plc, Illumina Inc., Apollo Hospitals, OPKO Health Inc., Revvity Inc., ARUP Laboratories Inc., Mayo Clinic Laboratories, Fulgent Genetics Inc., MedGenome Inc., Genome Medical, PreventionGenetics, Eurofins Genomics LLC, Blueprint Genetics Inc., MapmyGenome, GENinCode, Allelica Srl, Rocket Pharma Inc., and Health in Code SL.

Global Cardiovascular Genetic Testing Market Trends and Insights

Major companies operating in the cardiovascular genetic testing market are focusing on developing innovative solutions, such as clinician-ordered tests, to help ensure the test is medically necessary and tailored to the patient’s specific health condition, reducing unnecessary testing and costs. A clinician-ordered test is a medical examination or diagnostic procedure requested by a healthcare professional to evaluate, monitor, or guide the management of a patient’s health condition. For instance, in September 2025, Mass General Brigham, a US-based not-for-profit integrated academic healthcare system, in collaboration with Broad Clinical Labs, a US-based genomic data generation laboratory, and Mass General Brigham Laboratory for Molecular Medicine, a US-based molecular diagnostic laboratory, launched a genetic test that evaluates inherited risk for eight cardiovascular conditions. The clinician-ordered test is offered on a self-pay basis and evaluates genetic predisposition to eight conditions, including atrial fibrillation, coronary artery disease, type 2 diabetes, elevated lipoprotein(a), hypercholesterolemia, hypertension, thoracic aortic aneurysm, and venous thromboembolism. Its development utilized genotype and clinical data from 236,393 participants in the NIH’s All of Us Research Program. Publicly available polygenic risk scores for each condition were integrated using PRSmix, an elastic-net modeling approach that combines multiple component scores into a single, comprehensive risk score per disease. High-resolution genetic data is captured through a clinical blended genome-exome assay at Broad Clinical Labs, while the CLIA-certified Mass General Brigham Laboratory for Molecular Medicine interprets the results and generates patient-friendly reports.

What Are Latest Mergers And Acquisitions In The Cardiovascular Genetic Testing Market?

In February 2025, Tempus AI Inc., a US-based precision medicine company, acquired Ambry Genetics for an undisclosed amount. The acquisition strengthens the strategy of leveraging diagnostics and data to drive innovation. It enhances the ability to deliver advanced solutions to clinicians, patients, and life sciences companies. Ambry Genetics Corporation is a US-based company specializing in cardiovascular genetic testing.

Regional Insights

North America was the largest region in the cardiovascular genetic testing market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Cardiovascular Genetic Testing Market?

The cardiovascular genetic testing market includes revenues earned by entities through genetic testing services, genetic screening services, molecular diagnostic services, genomic sequencing services, variant interpretation services, bioinformatics analysis services, genetic counseling services, and personalized risk assessment services. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Cardiovascular Genetic Testing Market Report 2026?

The cardiovascular genetic testing market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the cardiovascular genetic testing industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.